tetano
Editor, Senior Moderator
Anal Chem
. 2021 Jan 29.
doi: 10.1021/acs.analchem.0c04303. Online ahead of print.
Detection of SARS-CoV-2 and Its Mutated Variants via CRISPR-Cas13-Based Transcription Amplification
Yuxi Wang[SUP] 1 [/SUP], Yong Zhang[SUP] 2 [/SUP], Junbo Chen[SUP] 3 [/SUP], Minjin Wang[SUP] 4 [/SUP], Ting Zhang[SUP] 2 [/SUP], Wenxin Luo[SUP] 1 [/SUP], Yalun Li[SUP] 1 [/SUP], Yangping Wu[SUP] 1 [/SUP], Bo Zeng[SUP] 1 [/SUP], Kaixiang Zhang[SUP] 5 [/SUP], Ruijie Deng[SUP] 2 [/SUP], Weimin Li[SUP] 1 [/SUP]
Affiliations
Abstract
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global health emergency, and its gene mutation and evolution further posed uncertainty of epidemic risk. Herein, we reported a light-up CRISPR-Cas13 transcription amplification method, which enables the detection of SARS-CoV-2 and its mutated variants. Sequence specificity was ensured by both the ligation process and Cas13a/crRNA recognition, allowing us to identify viral RNA mutation. Light-up RNA aptamer allows sensitive output of amplification signals via target-activated ribonuclease activity of CRISPR-Cas13a. The RNA virus assay has been designed to detect coronavirus, SARS-CoV-2, Middle East respiratory syndrome (MERS), and SARS, as well as the influenza viruses such as, H1N1, H7N9, and H9N2. It was accommodated to sense as low as 82 copies of SARS-CoV-2. Particularly, it allowed us to strictly discriminate key mutation of the SARS-CoV-2 variant, D614G, which may induce higher epidemic and pathogenetic risk. The proposed RNA virus assays are promising for point-of-care monitoring of SARS-CoV-2 and its risking variants.
. 2021 Jan 29.
doi: 10.1021/acs.analchem.0c04303. Online ahead of print.
Detection of SARS-CoV-2 and Its Mutated Variants via CRISPR-Cas13-Based Transcription Amplification
Yuxi Wang[SUP] 1 [/SUP], Yong Zhang[SUP] 2 [/SUP], Junbo Chen[SUP] 3 [/SUP], Minjin Wang[SUP] 4 [/SUP], Ting Zhang[SUP] 2 [/SUP], Wenxin Luo[SUP] 1 [/SUP], Yalun Li[SUP] 1 [/SUP], Yangping Wu[SUP] 1 [/SUP], Bo Zeng[SUP] 1 [/SUP], Kaixiang Zhang[SUP] 5 [/SUP], Ruijie Deng[SUP] 2 [/SUP], Weimin Li[SUP] 1 [/SUP]
Affiliations
- PMID: 33511840
- DOI: 10.1021/acs.analchem.0c04303
Abstract
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global health emergency, and its gene mutation and evolution further posed uncertainty of epidemic risk. Herein, we reported a light-up CRISPR-Cas13 transcription amplification method, which enables the detection of SARS-CoV-2 and its mutated variants. Sequence specificity was ensured by both the ligation process and Cas13a/crRNA recognition, allowing us to identify viral RNA mutation. Light-up RNA aptamer allows sensitive output of amplification signals via target-activated ribonuclease activity of CRISPR-Cas13a. The RNA virus assay has been designed to detect coronavirus, SARS-CoV-2, Middle East respiratory syndrome (MERS), and SARS, as well as the influenza viruses such as, H1N1, H7N9, and H9N2. It was accommodated to sense as low as 82 copies of SARS-CoV-2. Particularly, it allowed us to strictly discriminate key mutation of the SARS-CoV-2 variant, D614G, which may induce higher epidemic and pathogenetic risk. The proposed RNA virus assays are promising for point-of-care monitoring of SARS-CoV-2 and its risking variants.